| Revenue guidance | 11.0% → 12.0% Raised by 1.0 percentage points |
|---|---|
| Management target | Revenue 12.0% FY27 |
| Revenue growth | 11% YoY total; India 10.3%, International 16%. |
|---|---|
| Margins | EBITDA 20.5%; target 7-8% improvement over 3-4 years. |
| Demand visibility | Positive on Chronic and Acute segments; Chronic outperforming market. |
| Management confidence | High on India outperformance and International sustainability. |
Growth
India sales at INR 2,497cr (10.3% YoY). International sales at INR 1,222cr (16% YoY). Branded generic growth was 12%.
Outlook
Guided India business growth to 12% for FY27. Gross margin guidance maintained at 66.5% to 67%. Targeting INR 400cr Occlutech sales.
Risks
Daman facility received OAI status. Trade Generics segment growth was flattish. US CDMO operations currently incur INR 60cr quarterly loss.
Last quarter's promises, checked
Delivered
- Guided 100-150bps India outperformance → delivered 10.3% vs 8-9% IPM (= BEAT)
- Guided 20-21% EBITDA margin → delivered 20.5% (= BEAT)
- Guided higher teen ROW growth → delivered 16% International (= BEAT)
Partly delivered
- Guided high single-digit US growth → delivered 16% Intl (US specifics mixed) (= PARTIAL)
Missed
- Guided trade generic improvement → delivered flattish growth (= MISS)
Investor Presentation filed with BSE, NSE: ALKEM. Summary written with AI assistance from the document.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,274.00
- Market cap
- ₹63,059 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.2×Sector 50.4×
- Promoter holding
- 49.70%-1.50% QoQ
- FII holding
- 10.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Management Change
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories Debt & Borrowing: ₹593.5 Cr
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
- Value
- ₹593.5 Cr
Alkem Laboratories Product Launch
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Alkem Laboratories Management Change
Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.
Alkem Laboratories Product Launch
Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.
Alkem Laboratories Q1 FY27 Results: Net Profit ₹521 Cr, Down 22.0% YoY
Alkem Laboratories Ltd reported revenue from operations of ₹3,740 Cr (+10.9% YoY) and net profit of ₹521 Cr (-22.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹521 Cr · -22.0% YoY